Literature DB >> 19500964

Heterologous prime-boost vaccination.

Shan Lu1.   

Abstract

An effective vaccine usually requires more than one time immunization in the form of prime-boost. Traditionally the same vaccines are given multiple times as homologous boosts. New findings suggested that prime-boost can be done with different types of vaccines containing the same antigens. In many cases such heterologous prime-boost can be more immunogenic than homologous prime-boost. Heterologous prime-boost represents a new way of immunization and will stimulate better understanding on the immunological basis of vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19500964      PMCID: PMC3743086          DOI: 10.1016/j.coi.2009.05.016

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  39 in total

Review 1.  The prime-boost concept applied to HIV preventive vaccines.

Authors:  J L Excler; S Plotkin
Journal:  AIDS       Date:  1997       Impact factor: 4.177

2.  Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

Authors:  S W Barnett; S Rajasekar; H Legg; B Doe; D H Fuller; J R Haynes; C M Walker; K S Steimer
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

3.  Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.

Authors:  T Hanke; R V Samuel; T J Blanchard; V C Neumann; T M Allen; J E Boyson; S A Sharpe; N Cook; G L Smith; D I Watkins; M P Cranage; A J McMichael
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

4.  Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting.

Authors:  He Xiao-wen; Sun Shu-han; Hu Zhen-lin; Li Jun; Jiang Lei; Zhou Feng-juan; Zhang Ya-nan; Guo Ying-jun
Journal:  Vaccine       Date:  2005-02-25       Impact factor: 3.641

5.  Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

Authors:  Shixia Wang; James Arthos; John M Lawrence; Donald Van Ryk; Innocent Mboudjeka; Siyuan Shen; Te-Hui W Chou; David C Montefiori; Shan Lu
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

Authors:  S L Hu; K Abrams; G N Barber; P Moran; J M Zarling; A J Langlois; L Kuller; W R Morton; R E Benveniste
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

7.  A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS.

Authors:  D Zagury; J Bernard; R Cheynier; I Desportes; R Leonard; M Fouchard; B Reveil; D Ittele; Z Lurhuma; K Mbayo
Journal:  Nature       Date:  1988-04-21       Impact factor: 49.962

8.  Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

Authors:  M Girard; M P Kieny; A Pinter; F Barre-Sinoussi; P Nara; H Kolbe; K Kusumi; A Chaput; T Reinhart; E Muchmore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

9.  Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

Authors:  J F Richmond; S Lu; J C Santoro; J Weng; S L Hu; D C Montefiori; H L Robinson
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

Authors:  S J Kent; A Zhao; S J Best; J D Chandler; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  187 in total

1.  DNA vaccination in the skin using microneedles improves protection against influenza.

Authors:  Jae-Min Song; Yeu-Chun Kim; Eunju O; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 2.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

3.  A field comparison of heterologous and homologous routes of administration of modified live vaccines for the control of bovine respiratory disease in recently weaned beef calves.

Authors:  Nathan Erickson; John Ellis; Cheryl Waldner; Herbert Lardner; Sheryl Gow; John Campbell; Adam Berenik
Journal:  Can Vet J       Date:  2020-05       Impact factor: 1.008

4.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

5.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

6.  Comparative efficacy of modified-live and inactivated vaccines in boosting responses to bovine respiratory syncytial virus following neonatal mucosal priming of beef calves.

Authors:  John Ellis; Sheryl Gow; Adam Berenik; Stacey Lacoste; Nathan Erickson
Journal:  Can Vet J       Date:  2018-12       Impact factor: 1.008

7.  Shortened Intervals during Heterologous Boosting Preserve Memory CD8 T Cell Function but Compromise Longevity.

Authors:  Emily A Thompson; Lalit K Beura; Christine E Nelson; Kristin G Anderson; Vaiva Vezys
Journal:  J Immunol       Date:  2016-02-22       Impact factor: 5.422

8.  Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines.

Authors:  Ebony Gary; Margaret O'Connor; Marita Chakhtoura; Virginie Tardif; Ogan K Kumova; Delphine C Malherbe; William F Sutton; Nancy L Haigwood; Michele A Kutzler; Elias K Haddad
Journal:  Vaccine       Date:  2020-04-10       Impact factor: 3.641

9.  Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

Authors:  Katherine A Richards; Francisco A Chaves; Shabnam Alam; Andrea J Sant
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

10.  Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.

Authors:  Kristel L Emmer; Lindsay Wieczorek; Steven Tuyishime; Sebastian Molnar; Victoria R Polonis; Hildegund C J Ertl
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.